Peer-reviewed paper highlights pain-free enzymatic approach for venous leg ulcers

A newly published study in the International Wound Journal suggests that SolasCure’s investigational Aurase Wound Gel (AWG) may offer effective debridement for chronic wounds without increasing patient pain.

The peer-reviewed dose escalation study assessed the application of tarumase, an enzyme originally derived from medical maggots and the active component in AWG, for the treatment of venous leg ulcers (VLUs). These painful, chronic wounds typically require thorough debridement, but current approaches often force a trade-off between speed and patient comfort. While autolytic methods are slow but painless, surgical or mechanical options are faster but often painful — sometimes requiring anaesthesia. Even enzymatic approaches can lead to pain for some patients.

Aurase Wound Gel delivers tarumase in a proprietary hydrogel formulation, aiming to provide a gentler alternative. The study explored tarumase at concentrations up to 11 U/mL and found no increase in patient-reported pain above baseline, either shortly after application or after 48–72 hours. This reinforces earlier Phase 2A findings suggesting that AWG is well tolerated, with a favourable safety profile. AWG is currently in Phase 2 trials for VLUs.

“This publication highlights AWG’s unique pain-free profile and patient-centric benefits – features often missing from current wound care options,” said David Goldsmith, senior medical advisor at SolasCure. “These findings underscore its potential to transform outcomes for people living with chronic wounds.”